Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

January 12, 2017- Interviewed by Steven E. Greer, MD

Jonathan Strosberg, MD of the Moffit Cancer center discusses the results published in the NEJM for a Phase-3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

This entry was posted in - NEJM, Oncology. Bookmark the permalink.

Leave a Reply